ArticleViruses2015
Evaluation of Signature Erosion in Ebola Virus Due to Genomic Drift and Its Impact on the Performance of Diagnostic Assays.
Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Evaluation of a Probe-Based Enrichment Protocol for Nanopore Sequencing of Zoonotic Viruses.Viruses · 2025Article
- Laboratory Validation of a Fully Automated Point-of-Care Device for High-Order Multiplexing Real-Time PCR Detection of Respiratory Pathogens.Diagnostics (Basel, Switzerland) · 2025Article
- Reality check: testing theFrontiers in cellular and infection microbiology · 2025Article
- Loop-mediated isothermal amplification assays for the detection of antimicrobial resistance elements in Vibrio cholera.BMC bioinformatics · 2024Article
- Real-time PCR assays that detect genes for botulinum neurotoxin A-G subtypes.Frontiers in microbiology · 2024Article
- Towards a post-pandemic future for global pathogen genome sequencing.PLoS biology · 2023Article
- Development and Optimization of an Unbiased, Metagenomics-Based Pathogen Detection Workflow for Infectious Disease and Biosurveillance Applications.Tropical medicine and infectious disease · 2023Article
- Enhanced Arbovirus Surveillance with High-Throughput Metatranscriptomic Processing of Field-Collected Mosquitoes.Viruses · 2022Article
- Evaluation of tangential flow filtration coupled to long-read sequencing for ostreid herpesvirus type 1 genome assembly.Microbial genomics · 2022Article
- Fast Evaluation of Viral Emerging Risks (FEVER): A computational tool for biosurveillance, diagnostics, and mutation typing of emerging viral pathogens.PLOS global public health · 2022Article
- Impact of SARS-CoV-2 Mutations on PCR Assay Sequence Alignment.Frontiers in public health · 2022Article
- Appendix Q: Recommendations for Developing Molecular Assays for Microbial Pathogen Detection Using Modern In Silico Approaches.Journal of AOAC International · 2020Article
- Viral genomics in Ebola virus research.Nature reviews. Microbiology · 2020Review
- Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance.Nature microbiology · 2020Article
- Pre-emptive genomic surveillance of emerging ebolaviruses.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
- Enrichment post-library preparation enhances the sensitivity of high-throughput sequencing-based detection and characterization of viruses from complex samples.BMC genomics · 2019Article
- Precision epidemiology for infectious disease control.Nature medicine · 2019Review
- Cutting-Edge Infectious Disease Diagnostics with CRISPR.Cell host & microbe · 2018Article
- Virus-encoded miRNAs in Ebola virus disease.Scientific reports · 2018Article
- Strategies in Ebola virus disease (EVD) diagnostics at the point of care.Critical reviews in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome sequence analyses of the 2014 Ebola Virus (EBOV) isolates revealed a potential problem with the diagnostic assays currently in use; i.e., drifting genomic profiles of the virus may affect the sensitivity or even produce false-negative results. We evaluated signature erosion in ebolavirus molecular assays using an in silico approach and found frequent potential false-negative and false-positive results. We further empirically evaluated many EBOV assays, under real time PCR conditions using EBOV Kikwit (1995) and Makona (2014) RNA templates. These results revealed differences in performance between assays but were comparable between the old and new EBOV templates. Using a whole genome approach and a novel algorithm, termed BioVelocity, we identified new signatures that are unique to each of EBOV, Sudan virus (SUDV), and Reston virus (RESTV). Interestingly, many of the current assay signatures do not fall within these regions, indicating a potential drawback in the past assay design strategies. The new signatures identified in this study may be evaluated with real-time reverse transcription PCR (rRT-PCR) assay development and validation. In addition, we discuss regulatory implications and timely availability to impact a rapidly evolving outbreak using existing but perhaps less than optimal assays versus redesign these assays for addressing genomic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.